Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 reports an intended sale of 15,091 Class A ordinary shares through Charles Schwab & Co., Inc. for an aggregate market value of $535,778, to be traded on NASDAQ approximately on 09/03/2025. The shares were acquired the same day by an employee stock option exercise and the transaction indicates a broker payment for a cashless exercise.
The filing also discloses insider sales by Eben Tessari during the prior three months totaling 261,881 shares for aggregate gross proceeds of $8,341,479 across seven transactions between 06/09/2025 and 08/18/2025. The filing provides specific trade dates, amounts, and proceeds but does not include additional context or reasons for the sales.
Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International (KNSA), reported multiple equity transactions from September 1–3, 2025. The filings show a series of restricted share unit (RSU) grants, option exercises and open-market trades executed pursuant to a 10b5-1 plan. On September 3, 2025 the reporting person exercised a share option for 11,000 Class A Ordinary Shares at an exercise price of $17.92 and sold 11,000 shares in the market at a weighted average price of $34.84. Several RSU awards and stock options were granted or recognized on September 1–2, 2025 with various vesting schedules; one option grant has an exercise price of $33.49 and expires August 31, 2035. Following the reported transactions the reporting person beneficially owned 38,011 Class A Ordinary Shares.
Ross Moat, Chief Corporate & Commercial Officer of Kiniksa Pharmaceuticals International (KNSA), reported multiple equity transactions on September 1-2, 2025. The filing shows grant and acquisition of restricted share units (RSUs) and a stock option, and reported dispositions of Class A ordinary shares at prices of $33.49 and $34.28. The derivative section shows an option for 39,364 Class A shares and RSUs representing 9,828 Class A shares, each with specified multi-year vesting schedules. Following the reported transactions, the Form 4 lists beneficial ownership figures for Class A ordinary shares in the range shown, with the last reported post-transaction direct ownership of 12,938 Class A ordinary shares. The filing includes detailed vesting terms: option vesting begins September 1, 2025, and RSUs vest over four-year schedules with 25% annual vesting.
Kiniksa Pharmaceuticals International reported Form 4 transactions for John F. Paolini, its Chief Medical Officer and a director. The filing shows multiple equity award grants and option/RSU issuances on September 1 and 2, 2025, including 9,828 RSUs, a 39,364-share option exercisable through 08/31/2035 at a $33.49 exercise price, and several additional RSU grants tied to prior grant dates. The report also discloses sales of Class A ordinary shares on September 1 (2,841 shares at $33.49) and September 2 (835 shares at $34.28). Post-transactions beneficial ownership totals are shown for each line and all holdings are reported as direct.
Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals International, plc (KNSA), reported multiple equity transactions on Form 4 covering September 1-2, 2025. The filing shows grant activity including 12,275 Restricted Share Units (RSUs), a 39,363-share option with a $33.49 exercise price and several additional RSU grants and awards. It also discloses sales of Class A Ordinary Shares: 2,920 shares sold at $33.49 and 900 shares sold at $34.28. Following the reported transactions, the filing lists varying beneficial ownership totals for each line item, with direct ownership reported for all items. The form is signed by an attorney-in-fact on behalf of the reporting person.
Kiniksa Pharmaceuticals director and Chairman & CEO Sanj K. Patel reported multiple transactions on Form 4 covering September 1-2, 2025. The filing shows grants of 34,435 restricted share units (RSUs), a 137,638-share option with a $33.49 exercise price, and additional RSU grants and deliveries on those dates. The report also discloses open-market disposals: 10,983 Class A shares sold at $33.49 and 3,177 Class A shares sold at $34.28. Following the transactions, Mr. Patel beneficially owns 109,795 shares indirectly held by The Marina 2016 Irrevocable Trust and reports various direct holdings reflected in the table. Vesting schedules are specified: RSUs generally vest over four years with 25% annual vesting and the option vests 25% after one year then monthly over three years.
Kiniksa Pharmaceuticals International, plc reported a Form 144 notice for the proposed sale of 11,000 Class A ordinary shares to be executed through Charles Schwab & Co., Inc. on 09/03/2025 with an aggregate market value of $383,203.00. The shares were acquired the same day via an employee stock option exercise and the transaction will use a broker payment for a cashless exercise. The filing lists 43,472,928 shares outstanding, and shows prior sales by Michael R. Megna of 15,211 shares on 06/03/2025 (gross proceeds $437,330) and 17,000 shares on 08/04/2025 (gross proceeds $549,936). The filer certifies no undisclosed material adverse information.
Kiniksa Pharmaceuticals International, plc filed a Form 8-K to let investors know it has posted a new investor presentation on its website at investors.kiniksa.com. The company plans to use this presentation, in whole or in part and potentially with modifications, in upcoming meetings with investors, analysts and other audiences.
The investor presentation is furnished as Exhibit 99.1 to this report, with an additional cover page interactive data file listed as Exhibit 104. The filing is informational and does not announce any specific transaction or financial results.
Kiniksa Pharmaceuticals insider transactions by COO Eben Tessari show a mix of purchases and sales executed under a 10b5-1 plan. The reporting person exercised 6,500 vested options at an exercise price of $8.83 on 08/18/2025, acquiring 6,500 Class A ordinary shares. On the same date the reporting person sold 16,100 shares at a weighted-average price of $33.77 and an additional 100 shares at $34.44, reducing beneficial ownership to 40,215 shares. The Form 4 notes the trades were effected pursuant to a 10b5-1 plan executed April 29, 2024, and the option is fully vested and exercisable through 09/16/2029.
Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 notice reports a proposed sale of 16,200 Class A ordinary shares through Charles Schwab, with an aggregate market value of $547,070, slated for 08/18/2025 on NASDAQ. The filing documents the acquisition history for those shares, including founders' shares from 09/16/2015, two performance award lapses in 03/2022 and 03/2023, and an 08/18/2025 cashless option exercise. The filer, identified by past sales as Eben Tessari at a Lexington, MA address, sold 257,681 shares across seven transactions in May–August 2025, generating total gross proceeds of $8,111,307. The notice includes the seller's representation about lack of undisclosed material adverse information.